Navigation Links
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib,Combination in Non-Small Cell Lung Cancer Presented at American,Association of Cancer Research Annual Meeting

imately 75-80% of NSCLCs," commented Jean Nichols, Ph.D., Executive Vice-President and Chief Scientific Officer at Gloucester.

"The preclinical synergy seen in this study provides a strong rationale for conducting clinical studies of the combination. If similar results are seen clinically, the potential exists to substantially increase the use of TKIs such as erlotinib in a broader population of lung cancer," she concluded.

About Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths worldwide. There are over 1.2 million cases of lung cancers every year in the world, and 1.1 million people will die from their disease. Non-small cell lung cancer accounts for approximately 80% of lung cancer.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops an
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

Post Your Comments:
(Date:11/6/2009)...ll/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KE...ber 10, 2009 at 8:30 a.m. EST to discuss the third...ok for the remainder of 2009. Ron Bentsur, Chief ...ll. Keryx will announce its financial results for... to the call. ,, In order to participate in the...
(Date:11/6/2009)...l/ -- Caraco Pharmaceutical Laboratories, Ltd. (NY...e ophthalmic solution, 0.5% following a final appr...) for Sun Pharma,s Abbreviated New Drug Applicatio...on on the first day following patent expiration. T...alent to Acular® Ophthalmic Solution, 0.5%, f...
(Date:11/5/2009)...wswire-FirstCall/ -- Transcept Pharmaceuticals, In...mpany focused on the development and commercializa...t therapeutic needs in the field of neuroscience, ...ference with management to discuss third quarter 2...09, at 5:00 p.m. Eastern Standard Time. Financial...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Keryx Biopharmaceuticals Phase 2 Data of KRX 0401 28Perifosine 29 in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Present 4998 1Keryx Biopharmaceuticals Phase 2 Data of KRX 0401 28Perifosine 29 in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Present 4998 2Keryx Biopharmaceuticals Phase 2 Data of KRX 0401 28Perifosine 29 in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Present 4998 3Communication problems in dementia care cause physical strain 57029 1Communication problems in dementia care cause physical strain 57029 2Evolution still scientifically stable 9912 1Evolution still scientifically stable 9912 2
...he University of,Maryland,s Maryland Industrial Pa...oval of 18 new collaborative research projects bet...Worth $4.4 million, the new projects combine $3 mi...n from the Maryland Industrial,Partnerships Progra...rch that furthers the,development of high-tech pro...
...b. 21 Flawed policies and,bad decisions at the FD...,clinical trials which now take an average of one ... This has delayed and even prevented the,availabil... in increased,death and suffering for patients and...in the United States., It,s time to reform the FD...
Other Medicine Technology:UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies 2UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies 3Cancer Cure Coalition Proposes Major Changes at the FDA 2Cancer Cure Coalition Proposes Major Changes at the FDA 3
(Date:11/8/2009)...lth advocates committed to achieving meaningful he... "Tonight the U.S. Hous...ice of America,s families by passing the Affordabl... deliver, without delay, on the promise of meaning... President and CEO of the National Alliance for Hi...
(Date:11/8/2009)...Secure the Stability of Medicare ,, HOUSTON, N...table to: J. James Rohack, M.D., President, Americ...newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ,...eform bill, which will help improve the health sys...t passage of H.R. 3961 to secure the stability of ...
(Date:11/8/2009)...rking Families vs. Insurance Companies ,, HARR...the heels of an historic late night vote in the Ho... care reform bill, the Pennsylvania AFL-CIO releas...ives voted on HR 3962, the Affordable Health Care ...sed Saturday evening by a vote of 220 to 215, take...
(Date:11/7/2009).../ -- Karen Ignagni, President and CEO of America,s...wing statement today on House passage of H.R. 3962...ve health care reform, and we have contributed to ...f how health insurance is provided. Earlier this y...of pre-existing condition exclusions, no longer ba...
(Date:11/7/2009)...- The American Medical Association (AMA) proudly p...ily Violence Prevention Fund, with the Citation fo...olicy-making meeting. The Citation for Distinguis...Delegates bestows on a non-physician. ,, (Log.../AMALOGO ) ,, "Ms. James has worked selflessl...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
... likely to reduce the risk of contacting HIV from .... A recent study involved 3,000 HIV negative men i...cised and other half were not circumcised. They ...umcised men contracted the virus. Further researc...
...olled for early health check up programs and atten...be healthier adults than those who do not. A ...ildren who had participated early in these health ... Early Education Program that had community based ...
... by the ‘Delhi High Court’ on Tuesday Justice Vikr... Hospital to compensate Manju a 12 year old for th...the hospital. He wanted to be informed in the next...eplacement and fixation of fracture dislocation of...
...e to Listeria can be life-threatening unless vigi...ing to the report published by Food Safety Author...tion can be as much as 30% associated with Listeri...ociated with L. monocytogenes is uncertain, howeve...
...g from problem gambling behavior may share their p...drug addicts and alcoholics. Researchers have...em gambling behavior in people and have found mark...vior may not represent the entire gamut of people ...
... Bath in England an interesting study has been con.../ men. This is despite the popular notion that th...one as yet knows. “Until fairly recently it ... the case,” said Dr Ed Keogh a psychologist from t...
Other Medicine News:Health News:Listeria Food Poisoning Can Be Dangerous In Pregnant Women And Elderly 2Health News:Gender difference in Pain Experience - Women feel More Pain than men 2
...to provide fast and accurate measurements of patie...identification and quantitation of hemoglobin vari...control., ,The A1c assay combines the speed an...affinity columns. The result is a precise assessme...
Roche COMPACT 3 Blood Gas Analyzer
IRMA TRUPOINT Blood Analysis System
Flatbed Agitator PFS42
Medicine Products: